Sodib7.5%

Sodib is indicated for the treatment and prevention of specific acid-base and electrolyte disturbances. Indications are classified below by strength of evidence.

Established/FDA-approved uses (parenteral)

• Treatment of metabolic acidosis associated with severe renal disease, uncontrolled diabetes mellitus (diabetic ketoacidosis, as adjunct therapy in severe cases with persistent acidosis despite fluid and insulin therapy), circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, and severe primary lactic acidosis.
• Adjunctive therapy in advanced cardiac life support for specific situations such as pre-existing metabolic acidosis, hyperkalemia, or tricyclic antidepressant overdose, per current resuscitation guidance (not for routine use in cardiac arrest).
• Severe salicylate or phenobarbital overdose, where urinary alkalinization increases renal elimination of the offending drug.

Established/OTC use (oral)

• Short-term, occasional relief of symptoms associated with hyperacidity, such as heartburn, acid indigestion, and upset stomach (antacid use).
• Urinary alkalinization for minor urinary discomfort or specific metabolic conditions, as directed by a physician.

Guideline-supported/adjunct use

• Management of chronic metabolic acidosis in chronic kidney disease, used under physician direction as an adjunct to overall management to help slow progression of renal disease.

Sodib is not a first-line treatment for routine diabetic ketoacidosis or most cases of cardiac arrest and should be used only under direct medical supervision when indicated.

Each unit of Sodium Bicarbonate contains Sodium Bicarbonate (NaHCO3) as the sole active ingredient. Sodium Bicarbonate is available in multiple dosage forms, including oral tablets/powder and parenteral (intravenous) injection solutions of varying strengths (e.g., 4.2%, 5%, 7.5%, 8.4%), formulated in water for injection, sometimes with disodium edetate as a stabilizer.

Sodib is an inorganic alkalinizing salt that dissociates in the body to provide bicarbonate ions, a key component of the blood's buffering system. Sodib is used medically to correct acidosis, alkalinize urine, and, taken orally, as a short-term antacid for symptomatic relief of excess stomach acid. Sodib is given orally for antacid and mild alkalinization purposes and intravenously for correction of significant metabolic acidosis and selected emergency indications, always under medical guidance for the parenteral route.

Alkalinizing agent; Antacid; Electrolyte replenisher.

Sodium Bicarbonate dissociates to provide bicarbonate (HCO3-) and sodium (Na+) ions. Bicarbonate is a normal constituent of body fluids and the principal extracellular buffer; it neutralizes excess hydrogen ions, raising blood and urinary pH. When given intravenously, Sodium Bicarbonate rapidly increases plasma bicarbonate concentration and buffers circulating hydrogen ion, raising blood pH and reversing clinical manifestations of acidosis. Taken orally, Sodium Bicarbonate reacts with gastric hydrochloric acid to form sodium chloride, water, and carbon dioxide, transiently neutralizing gastric acidity. Alkalinization of urine with Sodium Bicarbonate increases the ionization and renal clearance of acidic drugs such as salicylates, while decreasing clearance of basic drugs.

Sodib injection is for intravenous use only, generally as a slow infusion (or, in emergencies, controlled slow IV push per protocol); rapid administration of Sodib should be avoided, particularly in neonates and infants, due to the risk of hypernatremia and intracranial hemorrhage. Sodib should not be mixed with calcium-containing solutions or catecholamines in the same IV line due to incompatibility. Oral Sodib (tablets or powder dissolved in water) should be taken with a full glass of water, preferably after meals; it should not be taken with, or immediately after, a large meal.

Sodib can cause clinically significant interactions through alteration of urinary pH and by direct chemical incompatibility.

• Salicylates and lithium: Urinary alkalinization from Sodib increases renal excretion of these drugs, potentially reducing their therapeutic effect (this effect is used therapeutically to hasten salicylate elimination in overdose).
• Amphetamines, quinidine, and other basic drugs: Alkaline urine caused by Sodib decreases their renal excretion, which can raise plasma levels and toxicity risk.
• Tetracycline antibiotics and iron salts: Concurrent oral use with Sodib may reduce absorption of these agents; separate doses by several hours.
• Enteric-coated medications: The alkaline environment produced by Sodib can cause premature dissolution of enteric coatings, leading to gastric irritation or reduced efficacy.
• Calcium-containing solutions/IV catecholamines: Physical/chemical incompatibility with Sodib in IV lines can cause precipitation or drug inactivation; administer through separate lines.
• Sodium-restricted regimens/other sodium products: Sodib adds to total sodium load; use cautiously in patients on salt-restricted diets (see Precautions and Warnings).

Adverse effects of Sodib are generally related to sodium and alkali load and are more likely with excessive or prolonged use.

• Common: Belching, flatulence, and gastric distension with oral Sodib, due to carbon dioxide release.
• Electrolyte/acid-base: Metabolic alkalosis, hypokalemia, hypernatremia, hypocalcemia (tetany in susceptible patients).
• Fluid-related: Fluid retention, edema, and, with high sodium load, worsening of hypertension or heart failure.
• Injection-site: Pain, irritation, and tissue necrosis if IV Sodib extravasates.
• Other (rare): Hypersensitivity reactions.

Formal controlled studies of Sodib in human pregnancy are limited. Sodib should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use, especially for anything beyond occasional, short-term antacid use. High-dose or prolonged use of Sodib in pregnancy could theoretically contribute to maternal fluid overload, alkalosis, or excess sodium load. During breastfeeding, occasional standard antacid doses of Sodib are generally considered acceptable, but a physician should be consulted before regular or high-dose use.

Sodib should be used with caution in the following situations:

• Renal impairment: Reduced ability to excrete excess sodium and bicarbonate increases the risk of fluid retention, edema, and metabolic alkalosis with Sodib.
• Heart failure, hypertension, or edematous states: The sodium load from Sodib can worsen fluid retention and blood pressure control.
• Risk of alkalosis: Excessive or prolonged use of Sodib can cause metabolic alkalosis, particularly with impaired renal function or concurrent vomiting/nasogastric suction (see Contraindications).
• IV administration: Requires monitoring of acid-base balance and serum electrolytes; extravasation of Sodib can cause tissue necrosis, so the IV site should be monitored closely.
• Oral antacid use: Sodib is intended for short-term or occasional use; persistent indigestion, heartburn, or stomach pain should be evaluated by a physician rather than treated indefinitely. Sodib should not be taken by patients with symptoms of appendicitis or acute abdominal conditions.
• Sodium-restricted diets: Each dose of Sodib adds to total sodium intake; patients on salt-restricted diets should use it only under medical advice.

Overdose or excessive use of Sodib can cause severe metabolic alkalosis, hypokalemia, hypernatremia, hypocalcemia with tetany, muscle twitching, confusion, seizures, and cardiac arrhythmias. If overdose of Sodib is suspected, seek immediate medical attention or contact emergency services or a poison control center. Management is supportive and typically undertaken in a hospital setting, including correction of fluid and electrolyte imbalances under close monitoring; no specific antidote exists.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric

Sodib may be used in infants and children for severe metabolic acidosis under close medical and laboratory supervision; rapid IV administration of Sodib should be avoided in neonates and young infants due to the risk of hypernatremia and intracranial hemorrhage. Oral antacid use of Sodib in young children should be under physician direction.

Elderly

Elderly patients, who more often have age-related decline in renal or cardiac function, should use Sodib cautiously, with attention to sodium load and monitoring for fluid retention or alkalosis.

Renal impairment

Use Sodib with caution and at reduced doses; monitor closely for sodium/fluid retention and alkalosis.

Hepatic impairment

No specific dose adjustment for Sodib is established; general precautions for sodium and fluid status apply.

Duration of Sodib therapy depends on the indication. Intravenous Sodib for acute metabolic acidosis is continued only until acid-base status is corrected, guided by laboratory monitoring, and under direct medical supervision. Oral antacid use of Sodib should be limited to short-term, occasional symptom relief (generally no more than 2 weeks) unless a physician directs longer use for a specific chronic condition, such as management of chronic metabolic acidosis in kidney disease.

Alkalinizing agents; Antacids; Electrolyte and acid-base balance agents.

Sodium Bicarbonate acts as a source of bicarbonate ion, the body's principal buffer base, which combines with excess hydrogen ions to neutralize acid and raise pH. Systemically, Sodium Bicarbonate corrects metabolic acidosis; in the stomach, Sodium Bicarbonate neutralizes hydrochloric acid to relieve symptoms of hyperacidity; in the renal tubules, the alkaline urine pH produced by Sodium Bicarbonate alters the ionization and reabsorption of certain drugs, changing their rate of excretion.

C

Sodib is used in pediatric patients, including neonates, for treatment of severe metabolic acidosis under close medical supervision, with dosing individualized to body weight and calculated bicarbonate deficit. In neonates and infants, slow administration of Sodib is essential, as rapid IV injection has been associated with hypernatremia, decreased cerebrospinal fluid pressure, and intracranial hemorrhage. Safety and efficacy of routine oral antacid use of Sodib in young children have not been well established, and such use should only occur under a physician's direction.